Full Length Research Paper
References
|
Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L (2007). Hormonal therapies for early breast cancer: Systematic review and economic evaluation. Health Technol. Assess. 11(26):iii-iv, ix-xi, 1-134. |
||||
|
Jahanzeb M (2007). Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Clin. Ther. 29(8):1535-1547. Crossref |
||||
|
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (2007). Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J. Natl. Cancer Inst. 99(4):272-282. Crossref |
||||
|
Zhou LX, Zhu J, Ding H, Jia CX, Xue SJ, Pan RK (2007). Changes in the sonographic appearance of the endometrium after different premenopausal tamoxifen therapies. Nan Fang Yi Ke Da Xue Xue Bao. 27(8):1227-1229. |
||||
|
Nelson AL (2010). Levonorgestrel intrauterine system: A first-line medical treatment for heavy menstrual bleeding. Women's Health (Lond Engl). 6(3):347-356. Crossref |
||||
|
O'Flynn N, Britten N (2004). Diagnosing menstrual disorders: A qualitative study of the approach of primary care professionals. Br. J. Gen. Pract. 54(502):353-358. |
||||
|
Istre O, Qvigstad E (2007). Current treatment options for abnormal uterine bleeding: An evidence-based approach. Best Pract. Res. Clin. Obstet. Gynaecol. 21(6):905-913. Crossref |
||||
|
EuroQol Group (1990). EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 16(3):199-208. Crossref |
||||
|
International Committee for Standardization in Hematology (1967). Recommendations for hemoglobinometry in human blood. Br. J. Haematol. 13(4):71-75. Crossref |
||||
| Siedel J (1984). Improved Ferrozine® based reagent for the determination of serum iron (transferrin iron) without deproteinization. Clin. Chem. 30(6):975. | ||||
|
Jacobs A, Path FRC, Warwood MJ (1975). Ferritin in serum. Clinical and biochemical implications. N. Engl. J. Med. 292(18):951-956. Crossref |
||||
|
Küçük T, Ertan K (2008). Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: A randomized, prospective, controlled clinical trial in female smokers. Clin. Exp. Obstet. Gynecol. 35(1):57-60. |
||||
|
Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM (2011). A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int. J. Gynaecol. Obstet. 112(2):126-130. Crossref |
||||
|
Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH (2011). Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: A randomized clinical trial. Contraception. 83(1):48-54. Crossref |
||||
|
Jensen JT, Nelson AL, Costales AC (2008). Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 77(1):22-29. Crossref |
||||
|
Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM (2010). Intrauterine device use among women with uterine fibroids: A systematic review. Contraception 82(1):41-55. Crossref |
||||
|
Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, Tjalma W (2007). Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: Long-term follow-up. Maturitas 57(2):210-213. Crossref |
||||
|
Chan SSC, Tam WH, Yeo W, Yu MMY, Ng DPS, Wong AWY, Kwan WH, Yuen PM (2007). A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 114(12):1510-1515. Crossref |
||||
|
Kesim MD, Aydin Y, Atis A, Mandiraci G (2008). Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 11(3):252-257. Crossref |
||||
|
Trinh XB, Tjalma WAA, Makar AP, Buytaert G, Weyler J, van Dam PA (2008). Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil. Steril. 90(1):17-22. Crossref |
||||
|
Qi X, Zhao W, Duan Y, Li Y (2008). Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia. Gynecol. Obstet. Invest. 65(4):266-268. Crossref |
||||
|
Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, Jun HS, Park CT (2010). The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J. Gynecol. Oncol. 21(2):102-105. Crossref |
||||
|
Koh SCL, Singh K (2010). Levonorgestrel-intrauterine system effects on hemostasis and menstrual blood loss in women seeking contraception. J. Obstet. Gynaecol. Res. 36(4):838-844. Crossref |
||||
|
Heikinheimo O, Inki P, Kunz M, Gemzell-Danielsson K (2010). Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system. Hum. Reprod. 25(6):1423-1427. Crossref |
||||
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
